SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
YMI: YM Biosciences, Inc. (YMI on AMEX)
An SI Board Since February 2006
Posts SubjectMarks Bans Symbol
66 9 0 YMI
Emcee:  FiloF Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
66Buyout by Gilead for $2.95/share. Wish I'd been sitting on more.caly-12/12/2012
65<i>(emphasis mine)</i> Leukemia. 2011 Sep 16. doi: 10.1038/leu.201scaram(o)uche-9/25/2011
64Ym Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announcescaly-10/14/2010
63One of my few bright spots, and unfortunately I don't have a large position.caly-10/2/2010
62From last month... YM BioSciences closes US$17.5 million financing MISSISSAUGAcaly-4/12/2010
61Ym Biosciences Reports Positive Nimotuzumab Four-Year Survival Data Presented atJohn McCarthy-11/3/2009
60Ym Biosciences Reports Additional Results From Nimotuzumab Phase III Study in ChJohn McCarthy-10/29/2009
59Dew <i>YM is developing AeroLEF for the treatment of moderate to severe aJohn McCarthy-10/6/2009
58<i>>YM is developing AeroLEF for the treatment of moderate to severe acDewDiligence_on_SI-10/6/2009
57YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEJohn McCarthy-10/6/2009
56Merck KGaA’s Erbitux Failed to Extend Lives in Study (Update3) By Naomi KresgeJohn McCarthy-9/27/2009
55Ym Biosciences Reports Fiscal Year End 2009 Operational and Financial Results PJohn McCarthy-9/25/2009
54Untangling the Nimotuzumab Conundrum An easy google or reading posts on Yahoo aJohn McCarthy-9/19/2009
53ncbi.nlm.nih.gov SearchL radiation dermatitis cetuximabJohn McCarthy-9/19/2009
52Severe skin reaction secondary to concomitant radiotherapy plus cetuximab BernhaJohn McCarthy-9/19/2009
51Hmmmm ... What changed? Erbitux (ceuximab) Approved for Use in Combination witJohn McCarthy-9/19/2009
50Cases J. 2009; 2: 25. Published online 2009 January 7. doi: 10.1186/1757-1626-2John McCarthy-9/19/2009
49T h e new engl and journa l o f medicine n engl j med 357;5 www.nejm.514 org augJohn McCarthy-9/19/2009
48Consensus guidelines for the management of radiation dermatitis and coexisting aJohn McCarthy-9/19/2009
47American Journal of Clinical Oncology: POST AUTHOR CORRECTIONS, 29 May 2009 John McCarthy-9/19/2009
46High rate of severe radiation dermatitis during radiation therapy with concurrenJohn McCarthy-9/19/2009
45Severe radiation dermatitis with concurrent cetuximab and radiation — There is aJohn McCarthy-9/19/2009
44These guys are tracking side effects and (I am guessing) refer to the "opinJohn McCarthy-9/19/2009
43Not sure if this is EXACTLY the presentation given at R&R - in any event - vJohn McCarthy-9/19/2009
42Page 4 of 31 Page 16 of 31 R&R presentation wsw.com at 7:00 Shares 58.0? CJohn McCarthy-9/19/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News